Evidence map›Paper›PMID 39468625›Full record

ArticleOrphanet journal of rare diseases2024

What is known about patients' quality of life with Phenylketonuria and their caregivers? A scoping review.

Eduardo Remor, Kamilla Mueller Gabe, Katia Irie Teruya, Ida Vanessa Doederlein Schwartz

Abstract readScoping Review
In one paragraph

Article in Orphanet journal of rare diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Observational
  2. Article
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eduardo RemorGraduate Program in Psychology, Institute of Psychology, Social Work, Health and Human Communication, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. eduardo.remor@ufrgs.br.ORCID 0000-0002-5393-8700
Kamilla Mueller GabeGraduate Program in Psychology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Katia Irie TeruyaGraduate Program in Psychology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.ORCID 0000-0002-4481-0086
Ida Vanessa Doederlein SchwartzDepartment of Genetics, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.ORCID 0000-0002-7933-6687

Funding

Conselho Nacional de Desenvolvimento Científico e Tecnológico 001Conselho Nacional de Desenvolvimento Científico e Tecnológico 313308/2021-7Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001
6 · The paper itself

Abstract

backgroundPhenylketonuria (PKU) is a rare genetic disorder characterized by a deficiency in the metabolism of the essential amino acid phenylalanine, which has a neurotoxic effect at high concentrations. The available treatment for PKU involves limiting the intake of phenylalanine through a restrictive diet. Strict adherence to treatment is essential for a child's proper development. Owing to their rare and chronic condition, PKU patients and their caregivers need to address many specific challenges, which can affect their quality of life (QoL). PURPOSE: This review aimed to identify, characterize, map, and summarize existing knowledge about the quality of life of PKU patients and their primary caregivers.

methodsA scoping review was conducted following the PRISMA-ScR guidelines. The PubMed, PsycINFO, EMBASE, Scopus, CINAHL, and BVS databases were searched, and articles published between January 2000 and February 2023 were included.

resultsThe search resulted in 3249 articles, 29 of which were selected for analysis. Most studies were cross-sectional, and the highest concentration of publications ranged between 2011 and 2021. Generic self-report questionnaires were the tools most commonly used to assess patients' and their caregivers' QoL. A significant negative impact on QoL was found in most studies with pediatric patients and caregivers. High current and lifetime blood Phe levels were associated with worse QoL in several domains, and higher tolerance of ingested phenylalanine was associated with a lower impact on QoL. Among caregivers, psychosocial variables such as stress, anxiety, depression, and child behavior problems were associated with poorer QoL. Higher perceived social and emotional support was a protective factor of QoL in caregivers.

conclusionPatients of pediatric age and their caregivers, younger caregivers, and female patients and caregivers seem to be especially vulnerable to QoL impairments. The social and emotional dimensions were the most affected. These results emphasize the importance of combining generic and disease-specific assessment tools to achieve a comprehensive assessment. Despite the growing interest in this topic, the longitudinal literature is limited, and there is a lack of interventional studies on this population. Future interventions addressing diet management and providing psychosocial support may benefit the QoL of the PKU population.

Indexed as

CaregiversPhenylketonuriasQuality of LifeHumansPhenylalaninePhenylalanineParentsPatientsPhenylketonuriaQuality of lifeScoping review

Identifiers

PMID39468625
PMCPMC11520463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.